Vorinostat in patients with resistant <i>BRAF<sup>V600E</sup></i> mutated advanced melanoma: a proof of concept study.

Huijberts, Sanne; Wang, Liqin; de Oliveira, Rodrigo Leite; Rosing, Hilde; Nuijen, Bastiaan; Beijnen, Jos; Bernards, Rene; Schellens, Jan; Wilgenhof, Sofie

Vorinostat in patients with resistant BRAF^V600E mutated advanced melanoma: a proof of concept study.

Huijberts, Sanne; Wang, Liqin; de Oliveira, Rodrigo Leite; Rosing, Hilde; Nuijen, Bastiaan; Beijnen, Jos; Bernards, Rene; Schellens, Jan; Wilgenhof, Sofie.

Affiliation

Huijberts S; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Wang L; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
de Oliveira RL; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Rosing H; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Nuijen B; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Beijnen J; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Bernards R; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Schellens J; Faculty of Science, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands.
Wilgenhof S; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.

Future Oncol ; 16(11): 619-629, 2020 Apr.

Article in En | MEDLINE | ID: mdl-32125175

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Histone Deacetylase Inhibitors/therapeutic use; Melanoma/drug therapy; Proto-Oncogene Proteins B-raf/genetics; Vorinostat/therapeutic use; Drug Administration Schedule; Drug Resistance, Neoplasm/genetics; Humans; MAP Kinase Signaling System/drug effects; MAP Kinase Signaling System/genetics; Melanoma/genetics; Melanoma/pathology; Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors; Mutation; Proof of Concept Study; Proto-Oncogene Proteins B-raf/antagonists & inhibitors

Key words

BRAF inhibitor; BRAFV600E mutation; MEK inhibitor; histone deacetylase inhibitor; melanoma; metastatic; resistance

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Proto-Oncogene Proteins B-raf / Histone Deacetylase Inhibitors / Vorinostat / Melanoma Limits: Humans Language: En Journal: Future Oncol Year: 2020 Type: Article Affiliation country: Netherlands

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google